+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Ruminant Vaccines Market Size, Share & Trends Analysis Report By Animal Type (Cattle, and Sheep & Goats), By Vaccines Type, By Route of Administration, By Indication, By Country and Growth Forecast, 2024 - 2031

  • PDF Icon

    Report

  • 135 Pages
  • April 2024
  • Region: Europe
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5955332
The Europe Ruminant Vaccines Market would witness market growth of 6.3% CAGR during the forecast period (2024-2031).

The Germany market dominated the Europe Ruminant Vaccines Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $331.1 million by 2031. The UK market is exhibiting a CAGR of 5.3% during (2024 - 2031). Additionally, The France market would experience a CAGR of 7.1% during (2024 - 2031).



Vaccines targeting respiratory pathogens such as Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Bovine Respiratory Syncytial Virus (BRSV) are used to prevent diseases like bovine respiratory disease complex (BRDC), contagious caprine pleuropneumonia (CCPP), and ovine pulmonary adenocarcinoma (OPA). Vaccination helps reduce the incidence and severity of respiratory infections, decrease antibiotic usage, and improve animal welfare.

Similarly, reproductive disorders can have significant economic implications for ruminant producers due to reduced fertility, abortions, and neonatal mortality. Vaccines targeting reproductive pathogens such as Brucella abortus, Chlamydia spp., and bovine herpesvirus 1 (BHV-1) are used to prevent diseases like brucellosis, campylobacteriosis, and infectious bovine rhinotracheitis (IBR). Vaccination helps maintain herd fertility, reduce reproductive losses, and prevent the spread of sexually transmitted infections among breeding animals.

Europe is a major meat producer, including beef, veal, lamb, and mutton. As per Eurostat, at the end of 2022, there were 134 million pigs, 75 million bovine animals, and 70 million sheep and goats in the EU. The EU produced a provisional 6.6 million tons of bovine meat (beef and veal carcasses) by 2022. About 70 % of the EU’s veal meat was produced in three countries, the Netherlands (26.9 %), Spain (22.9 %), and France (18.9 %). In conclusion, the region’s high meat production promotes the market’s growth.

Based on Animal Type, the market is segmented into Cattle, and Sheep & Goats. Based on Vaccines Type, the market is segmented into Modified/ Attenuated Live, Inactivated (Killed), and Others. Based on Route of Administration, the market is segmented into Injectable, and Intranasal. Based on Indication, the market is segmented into Bovine Respiratory Diseases (BRD), Diarrhea/ Scours, FMD, Clostridial Diseases, Leptospirosis, BVD Infection, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled

  • Boehringer Ingelheim International GmbH
  • Zoetis, Inc.
  • Merck & Co., Inc.
  • Bimeda, Inc.
  • Elanco Animal Health, Inc.
  • Virbac
  • Ceva Sante Animale
  • CZ Vaccines S.A.U. (Zendal Health S.A.)
  • Indian Immunologicals Ltd. (National Dairy Development Board)
  • Vaxxinova International BV (EW Group)

Market Report Segmentation

By Animal Type
  • Cattle
  • Sheep & Goats
By Vaccines Type
  • Modified/ Attenuated Live
  • Inactivated (Killed)
  • Others
By Route of Administration
  • Injectable
  • Intranasal
By Indication
  • Bovine Respiratory Diseases (BRD)
  • Diarrhea/ Scours
  • FMD
  • Clostridial Diseases
  • Leptospirosis
  • BVD Infection
  • Others
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Ruminant Vaccines Market, by Animal Type
1.4.2 Europe Ruminant Vaccines Market, by Vaccines Type
1.4.3 Europe Ruminant Vaccines Market, by Route of Administration
1.4.4 Europe Ruminant Vaccines Market, by Indication
1.4.5 Europe Ruminant Vaccines Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Opportunities
3.2.3 Market Restraints
3.2.4 Market Challenges
3.3 Porter’s Five Forces Analysis
Chapter 4. Recent strategies deployed in Ruminant Vaccines Market
Chapter 5. Europe Ruminant Vaccines Market by Animal Type
5.1 Europe Cattle Market by Country
5.2 Europe Sheep & Goats Market by Country
Chapter 6. Europe Ruminant Vaccines Market by Vaccines Type
6.1 Europe Modified/ Attenuated Live Market by Country
6.2 Europe Inactivated (Killed) Market by Country
6.3 Europe Others Market by Country
Chapter 7. Europe Ruminant Vaccines Market by Route of Administration
7.1 Europe Injectable Market by Country
7.2 Europe Intranasal Market by Country
Chapter 8. Europe Ruminant Vaccines Market by Indication
8.1 Europe Bovine Respiratory Diseases (BRD) Market by Country
8.2 Europe Diarrhea/ Scours Market by Country
8.3 Europe FMD Market by Country
8.4 Europe Clostridial Diseases Market by Country
8.5 Europe Leptospirosis Market by Country
8.6 Europe BVD Infection Market by Country
8.7 Europe Others Market by Country
Chapter 9. Europe Ruminant Vaccines Market by Country
9.1 Germany Ruminant Vaccines Market
9.1.1 Germany Ruminant Vaccines Market by Animal Type
9.1.2 Germany Ruminant Vaccines Market by Vaccines Type
9.1.3 Germany Ruminant Vaccines Market by Route of Administration
9.1.4 Germany Ruminant Vaccines Market by Indication
9.2 UK Ruminant Vaccines Market
9.2.1 UK Ruminant Vaccines Market by Animal Type
9.2.2 UK Ruminant Vaccines Market by Vaccines Type
9.2.3 UK Ruminant Vaccines Market by Route of Administration
9.2.4 UK Ruminant Vaccines Market by Indication
9.3 France Ruminant Vaccines Market
9.3.1 France Ruminant Vaccines Market by Animal Type
9.3.2 France Ruminant Vaccines Market by Vaccines Type
9.3.3 France Ruminant Vaccines Market by Route of Administration
9.3.4 France Ruminant Vaccines Market by Indication
9.4 Russia Ruminant Vaccines Market
9.4.1 Russia Ruminant Vaccines Market by Animal Type
9.4.2 Russia Ruminant Vaccines Market by Vaccines Type
9.4.3 Russia Ruminant Vaccines Market by Route of Administration
9.4.4 Russia Ruminant Vaccines Market by Indication
9.5 Spain Ruminant Vaccines Market
9.5.1 Spain Ruminant Vaccines Market by Animal Type
9.5.2 Spain Ruminant Vaccines Market by Vaccines Type
9.5.3 Spain Ruminant Vaccines Market by Route of Administration
9.5.4 Spain Ruminant Vaccines Market by Indication
9.6 Italy Ruminant Vaccines Market
9.6.1 Italy Ruminant Vaccines Market by Animal Type
9.6.2 Italy Ruminant Vaccines Market by Vaccines Type
9.6.3 Italy Ruminant Vaccines Market by Route of Administration
9.6.4 Italy Ruminant Vaccines Market by Indication
9.7 Rest of Europe Ruminant Vaccines Market
9.7.1 Rest of Europe Ruminant Vaccines Market by Animal Type
9.7.2 Rest of Europe Ruminant Vaccines Market by Vaccines Type
9.7.3 Rest of Europe Ruminant Vaccines Market by Route of Administration
9.7.4 Rest of Europe Ruminant Vaccines Market by Indication
Chapter 10. Company Profiles
10.1 Boehringer Ingelheim International GmbH
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Regional & Segmental Analysis
10.1.4 Research & Development Expenses
10.1.5 Recent strategies and developments:
10.1.5.1 Partnerships, Collaborations, and Agreements:
10.1.5.2 Product Launches and Product Expansions:
10.1.5.3 Geographical Expansions:
10.1.6 SWOT Analysis
10.2 Zoetis, Inc.
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expenses
10.2.5 Recent strategies and developments:
10.2.5.1 Product Launches and Product Expansions:
10.2.6 SWOT Analysis
10.3 Merck & Co., Inc.
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Segmental and Regional Analysis
10.3.4 Research & Development Expenses
10.3.5 Recent strategies and developments:
10.3.5.1 Product Launches and Product Expansions:
10.3.6 SWOT Analysis
10.4 Bimeda, Inc.
10.4.1 Company Overview
10.4.2 SWOT Analysis
10.5 Elanco Animal Health, Inc.
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Regional Analysis
10.5.4 Research & Development Expenses
10.5.5 SWOT Analysis
10.6 Virbac
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Regional Analysis
10.6.4 SWOT Analysis
10.7 Ceva Sante Animale
10.7.1 Company Overview
10.7.2 Recent strategies and developments:
10.7.2.1 Acquisition and Mergers:
10.7.3 SWOT Analysis
10.8 CZ Vaccines S.A.U. (Zendal Health S.A.)
10.8.1 Company Overview
10.8.2 SWOT Analysis
10.9 Indian Immunologicals Ltd. (National Dairy Development Board)
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Research & Development Expenses
10.9.4 SWOT Analysis
10.10. Vaxxinova International BV (EW Group)
10.10.1 Company Overview
10.10.2 SWOT Analysis

Companies Mentioned

  • Boehringer Ingelheim International GmbH
  • Zoetis, Inc.
  • Merck & Co., Inc.
  • Bimeda, Inc.
  • Elanco Animal Health, Inc.
  • Virbac
  • Ceva Sante Animale
  • CZ Vaccines S.A.U. (Zendal Health S.A.)
  • Indian Immunologicals Ltd. (National Dairy Development Board)
  • Vaxxinova International BV (EW Group)

Methodology

Loading
LOADING...